4//SEC Filing
Stauderman Kenneth A. 4
Accession 0001209191-23-020679
CIK 0001534133other
Filed
Mar 21, 8:00 PM ET
Accepted
Mar 22, 8:49 PM ET
Size
35.2 KB
Accession
0001209191-23-020679
Insider Transaction Report
Form 4
Stauderman Kenneth A.
Chief Scientific Officer
Transactions
- Award
Common Stock
2023-03-20+11,944→ 11,944 total - Award
Employee Stock Option (right to buy)
2023-03-20+22,777→ 22,777 totalExercise: $2.44Exp: 2028-08-01→ Common Stock (22,777 underlying) - Award
Employee Stock Option (right to buy)
2023-03-20+8,640→ 8,640 totalExercise: $2.44Exp: 2029-04-24→ Common Stock (8,640 underlying) - Award
Employee Stock Option (right to buy)
2023-03-20+21,647→ 21,647 totalExercise: $6.60Exp: 2030-06-29→ Common Stock (21,647 underlying) - Award
Employee Stock Option (right to buy)
2023-03-20+1,954→ 1,954 totalExercise: $10.42Exp: 2032-08-30→ Common Stock (1,954 underlying) - Award
Employee Stock Option (right to buy)
2023-03-20+2,090→ 2,090 totalExercise: $17.34Exp: 2033-03-19→ Common Stock (2,090 underlying) - Award
Employee Stock Option (right to buy)
2023-03-20+1,877→ 1,877 totalExercise: $17.34Exp: 2023-03-19→ Common Stock (1,877 underlying) - Award
Employee Stock Option (right to buy)
2023-03-20+7,264→ 7,264 totalExercise: $7.99Exp: 2031-04-27→ Common Stock (7,264 underlying) - Award
Employee Stock Option (right to buy)
2023-03-20+13,147→ 13,147 totalExercise: $7.99Exp: 2031-04-27→ Common Stock (13,147 underlying) - Award
Employee Stock Option (right to buy)
2023-03-20+7,264→ 7,264 totalExercise: $7.99Exp: 2031-06-30→ Common Stock (7,264 underlying) - Award
Employee Stock Option (right to buy)
2023-03-20+5,472→ 5,472 totalExercise: $19.45Exp: 2032-07-12→ Common Stock (5,472 underlying) - Award
Employee Stock Option (right to buy)
2023-03-20+661→ 661 totalExercise: $10.42Exp: 2032-08-30→ Common Stock (661 underlying) - Award
Employee Stock Option (right to buy)
2023-03-20+18,991→ 18,991 totalExercise: $17.34Exp: 2033-03-19→ Common Stock (18,991 underlying)
Footnotes (17)
- [F1]Received in exchange for 414,706 shares of common stock of CalciMedica, Inc. ("CalciMedica") pursuant to an Agreement and Plan of Merger and Reorganization (the "Merger Agreement") by and among CalciMedica, the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"). Under the terms of the Merger Agreement, on March 20, 2023, Merger Sub merged with and into CalciMedica (the "Merger"), with CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc.
- [F10]Received in exchange for a stock option to acquire 456,522 shares of common stock of CalciMedica pursuant to the Merger Agreement.
- [F11]Received in exchange for a stock option to acquire 190,000 shares of common stock of CalciMedica pursuant to the Merger Agreement.
- [F12]Received in exchange for a stock option to acquire 22,977 shares of common stock of CalciMedica pursuant to the Merger Agreement.
- [F13]Received in exchange for a stock option to acquire 67,873 shares of common stock of CalciMedica pursuant to the Merger Agreement.
- [F14]Beginning on November 22, 2022, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.
- [F15]Received in exchange for a stock option to acquire 72,589 shares of common stock of CalciMedica pursuant to the Merger Agreement.
- [F16]Received in exchange for a stock option to acquire 659,413 shares of common stock of CalciMedica pursuant to the Merger Agreement.
- [F17]Received in exchange for a stock option to acquire 65,191 shares of common stock of CalciMedica pursuant to the Merger Agreement.
- [F2]Immediately exercisable.
- [F3]Received in exchange for a stock option to acquire 790,880 shares of common stock of CalciMedica pursuant to the Merger Agreement.
- [F4]Upon the closing of the Merger, each outstanding option to purchase shares of CalciMedica common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock.
- [F5]Received in exchange for a stock option to acquire 300,000 shares of common stock of CalciMedica pursuant to the Merger Agreement.
- [F6]25% of the shares subject to the option vested on June 30, 2020 and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter.
- [F7]Received in exchange for a stock option to acquire 751,649 shares of common stock of CalciMedica pursuant to the Merger Agreement.
- [F8]Beginning on February 22, 2021, the shares subject to the option vest in a series of forty-eight (48) successive equal monthly installments.
- [F9]Received in exchange for a stock option to acquire 252,226 shares of common stock of CalciMedica pursuant to the Merger Agreement.
Documents
Issuer
CalciMedica, Inc. /DE/
CIK 0001534133
Entity typeother
Related Parties
1- filerCIK 0001969388
Filing Metadata
- Form type
- 4
- Filed
- Mar 21, 8:00 PM ET
- Accepted
- Mar 22, 8:49 PM ET
- Size
- 35.2 KB